The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
Laila Abdullah, Fiona Crawford, Magda Tsolaki, Anne Börjesson-Hanson, Marcel Olde Rikkert, Florence Pasquier, Anders Wallin, Sean Kennelly, Ghania Ait-Ghezala, Daniel Paris, Suzanne Hendrix, Kaj Blennow, Brian Lawlor, Michael Mullan, Laila Abdullah, Fiona Crawford, Magda Tsolaki, Anne Börjesson-Hanson, Marcel Olde Rikkert, Florence Pasquier, Anders Wallin, Sean Kennelly, Ghania Ait-Ghezala, Daniel Paris, Suzanne Hendrix, Kaj Blennow, Brian Lawlor, Michael Mullan
Abstract
We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity. Exploratory analyses were performed on the dataset (n = 497) of a phase III randomized placebo-controlled trial to examine the response to nilvadipine in AD subjects stratified by baseline AD severity into very mild (MMSE ≥ 25), mild (MMSE 20-24) and moderate AD (MMSE < 20). The outcome measures included total and subscale scores of the Alzheimer's Disease Assessment Scale Cognitive 12 (ADAS-Cog 12), the Clinical Dementia Rating Scale sum of boxes (CDR-sb) and the AD composite score (ADCOMS). Cerebrospinal fluid biomarkers Aβ38, Aβ40, Aβ42, neurofilament light chain (NFL), neurogranin, YKL-40, total tau and P181 tau (ptau) were measured in a subset of samples (n = 55). Regression analyses were adjusted for confounders to specifically examine the influence of nilvadipine and baseline AD severity on cognitive outcomes over 78-weeks. Compared to their respective placebo-controls, nilvadipine-treated, very mild AD subjects showed less decline, whereas moderate AD subjects showed a greater cognitive decline on the ADAS-Cog 12 test and the ADCOMS. A lower decline was observed after nilvadipine treatment for a composite memory trait in very mild AD subjects and a composite language trait in mild AD subjects. Cerebrospinal fluid Aβ42/Aβ40 ratios were increased in mild AD and decreased in moderate AD patients treated with nilvadipine, compared to their respective controls. Among moderate AD subjects, levels of ptau, total tau, neurogranin and YKL-40 increased in subjects treated with nilvadipine compared to placebo. These studies suggest that baseline AD severity influenced the treatment outcome in the NILVAD trial and that future clinical trials of nilvadipine should be restricted to mild and very mild AD patients. Trial Registration: NCT02017340 Registered 20 December 2013, https://ichgcp.net/clinical-trials-registry/NCT02017340 EUDRACT Reference Number 2012-002764-27 Registered 04 February 2013, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27.
Keywords: cerebrospinal fluid Aβ42/Aβ40 ratios; cognitive decline; exploratory analysis; mild Alzheimer's disease; nilvadipine.
Copyright © 2020 Abdullah, Crawford, Tsolaki, Börjesson-Hanson, Olde Rikkert, Pasquier, Wallin, Kennelly, Ait-Ghezala, Paris, Hendrix, Blennow, Lawlor and Mullan.
Figures
References
- Davies P. Neurochemical studies: an update on Alzheimer's disease. J Clin Psychiatry. (1988) 49(Suppl.):23–8.
- Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH. Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. Curr Opin Neurol. (2000) 13:377–84. 10.1097/00019052-200008000-00003
- Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. . Alzheimer's disease. Lancet. (2016) 388:505–17. 10.1016/S0140-6736(15)01124-1
- Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis. (2012) 30(Suppl. 2):S251–S268. 10.3233/JAD-2012-111376
- Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C, et al. . Non-alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. (2013) 126:365–84. 10.1007/s00401-013-1157-y
- James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. Tdp-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain. (2016) 139:2983–93. 10.1093/brain/aww224
- Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. (2014) 370:311–21. 10.1056/NEJMoa1312889
- Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D, et al. . Amyloid pet screening for enrichment of early-stage alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord. (2016) 30:1–7. 10.1097/WAD.0000000000000144
- Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, et al. . (2017) 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (lipididiet): a randomised, double-blind, controlled trial. Lancet Neurol. 16:965–75. 10.1016/S1474-4422(17)30332-0
- Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. . Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. (2018) 378:321–30. 10.1056/NEJMoa1705971
- Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, et al. . Delayed-start analyses in the phase 3 solanezumab expedition3 study in mild Alzheimer's disease. J Prev Alzheimers Dis. (2018) 5:8–14. 10.14283/jpad.2018.1
- Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, et al. . Nilvadipine antagonizes both abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in appsw transgenic mice. Brain Res. (2004) 999:53–61. 10.1016/j.brainres.2003.11.061
- Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, et al. . Selective antihypertensive dihydropyridines lower abeta accumulation by targeting both the production and the clearance of abeta across the blood-brain barrier. Mol Med. (2011) 17:149–62. 10.2119/molmed.2010.00180
- Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, et al. . The spleen tyrosine kinase (syk) regulates alzheimer amyloid-beta production and tau hyperphosphorylation. J Biol Chem. (2014) 289:33927–44. 10.1074/jbc.M114.608091
- Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier. Eur J Pharmacol. (2011) 659:124–9. 10.1016/j.ejphar.2011.03.048
- Morin A, Mouzon B, Ferguson S, Paris D, Saltiel N, Lungmus C, et al. . Treatment with nilvadipine mitigates inflammatory pathology and improves spatial memory in aged htau mice after repetitive mild TBI. Front Aging Neurosci. (2018) 10:292. 10.3389/fnagi.2018.00292
- Hanyu H, Hirao K, Shimizu S, Sato T, Kiuchi A, Iwamoto T. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiatry. (2007) 22:1264–6. 10.1002/gps.1851
- Lawlor B, Segurado R, Kennelly S, Olde Rikkert M.G. M., Howard R, et al. . Nilvadipine in mild to moderate alzheimer disease: a randomised controlled trial. PLoS Med. (2018) 15:e1002660. 10.1371/journal.pmed.1002660
- Verma N, Beretvas SN, Pascual B, Masdeu JC, Markey MK, Alzheimer's Disease Neuroimaging I. New scoring methodology improves the sensitivity of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-COG) in clinical trials. Alzheimers Res Ther. (2015) 7:64. 10.1186/s13195-015-0151-0
- Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, et al. . Adcoms: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatr. (2016) 87:993–9. 10.1136/jnnp-2015-312383
- Lawlor B, Kennelly S, O'Dwyer S, Cregg F, Walsh C, Coen R, et al. . Nilvad protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open. (2014) 4:e006364. 10.1136/bmjopen-2014-006364
- Meulenbroek O, O'Dwyer S, de Jong D, van Spijker G, Kennelly S, Cregg F, et al. . European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: nilvad frailty; nilvad blood and genetic biomarkers; nilvad cerebrospinal fluid biomarkers; nilvad cerebral blood flow. BMJ Open. (2016) 6:e011584. 10.1136/bmjopen-2016-011584
- Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. . Csf biomarker variability in the Alzheimer's association quality control program. Alzheimers Dement. (2013) 9:251–61. 10.1016/j.jalz.2013.01.010
- Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between csf biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. (2006) 5:228–34. 10.1016/S1474-4422(06)70355-6
- Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. . Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol. Med. (2016) 8:1184–1196. 10.15252/emmm.201606540
- Hansson O, Janelidze S, Hall S, Magdalinou N, Lees A, Andreasson U, et al. . Blood-based NFL: a biomarker for differential diagnosis of Parkinsonian disorder. Neurology. (2017) 88:930–7. 10.1212/WNL.0000000000003680
- Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. . Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Mol Med. (2019) 11:e11170. 10.15252/emmm.201911170
- Huntley J, Bor D, Hampshire A, Owen A, Howard R. Working memory task performance and chunking in early Alzheimer's disease. Br J Psychiatry. (2011) 198:398–403. 10.1192/bjp.bp.110.083857
- Hendrix S, Logovinsky V, Perdomo C, Wang J, Satlin A. Introducing a new tool for optimizing responsiveness to decline in early ad. Alzheimer's Dement. (2012) 8:S764–5. 10.1016/j.jalz.2013.08.086
- Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge KC, Wessels AM, et al. . Statistical properties of continuous composite scales and implications for drug development. J Biopharm Stat. (2017) 27:1104–14. 10.1080/10543406.2017.1315819
- Serrano-Pozo A, Qian J, Muzikansky A, Monsell SE, Montine TJ, Frosch MP, et al. Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum. J Neuropathol Exp Neurol. (2016) 75:516–26. 10.1093/jnen/nlw026
- Furman JL, Vaquer-Alicea J, White C, III, Cairns NJ, Nelson PT, Diamond MI. Widespread tau seeding activity at early braak stages. Acta Neuropathol. (2017) 133:91–100. 10.1007/s00401-016-1644-z
- Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. . Recent publications from the Alzheimer's disease neuroimaging initiative: reviewing progress toward improved ad clinical trials. Alzheimers. Dement. (2017) 13:e1–e85. 10.1016/j.jalz.2016.10.006
- Knopman DS. Clinical trial design issues in mild to moderate Alzheimer disease. Cogn Behav Neurol. (2008) 21:197–201. 10.1097/WNN.0b013e318190cf75
- Posner H, Curiel R, Edgar C, Hendrix S, Liu E, Loewenstein DA, et al. . Outcomes assessment in clinical trials of Alzheimer's disease and its precursors: readying for short-term and long-term clinical trial needs. Innov Clin Neurosci. (2017) 14:22–29.
- Hendrix S, Visser PJ, Solomon A, Kivipelto M, Hartmann T. Adcoms: A Post-Hoc Analysis Using Data From the Lipididiet Trial in Prodromal Alzheimer's Disease. Barcelona: CTAD; (2018).
- Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai YK, et al. Treatment of early ad subjects with ban2401, an ANTI-Aβ protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline. Alzheimer's Dement J Alzheimer's Assoc. (2018) 14:P1668 10.1016/j.jalz.2018.07.009
- Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F, et al. . The cerebrospinal fluid abeta1-42/abeta1-40 ratio improves concordance with amyloid-pet for diagnosing Alzheimer's disease in a clinical setting. J Alzheimers Dis. (2017) 60:561–76. 10.3233/JAD-170327
- Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, et al. . Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the world federation of societies of biological psychiatry. World J Biol Psychiatry. (2018) 19:244–328. 10.1080/15622975.2017.1375556
- de Jong DLK, de Heus RA, Rijpma A, Donders R, Rikkert O, Günther M, et al. . Effects of nilvadipine on cerebral blood flow in patients with Alzheimer disease. Hypertension. (2019) 74:413–20. 10.1161/HYPERTENSIONAHA.119.12892
- Sagare AP, Bell RD, Zlokovic BV. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in alzheimer disease. Cold Spring Harb Perspect Med. (2012) 2:a011452. 10.1101/cshperspect.a011452
- Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, et al. . Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years. Alzheimers Dement. (2018) 14:62–70. 10.1016/j.jalz.2017.06.2264
- Barrera-Ocampo A, Lopera F. Amyloid-beta immunotherapy: the hope for Alzheimer disease? Colomb. Med. (Cali). (2016) 47:203–12. 10.25100/cm.v47i4.2640
- Abdullah L, Crawford F, Langlois H, Tsolaki M, Börjesson-Hanson A, Olde Rikkert M, et al. Exploratory analyses suggest less cognitive decline with nilvadipine treatment in very mild Alzheimer's disease subjects. BioRxiv. (2018) 345652 10.1101/345652
Source: PubMed